"name","studyDesignRationale","id","description","uuid:ID","label"
"Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","The main design for the study","5f5ef3d7-e2f1-413a-a8b2-3f55a310d073",""
